Krankheitsmodifizierende Therapien bei Multisystematrophie

Melden Sie sich bitte hier kostenlos und unverbindlich an, um den Inhalt vollständig einzusehen und weitere Services von www.medmedia.at zu nutzen.

Zur Anmeldung

AutorIn: Dr. Victoria Sidoroff

Dysautonomie-Zentrum, Abteilung für klinische Neurobiologie, Universitätsklinik für Neurologie, Medizinische Universität Innsbruck


AutorIn: Univ.-Prof. DDr. Gregor Wenning, MSc

Dysautonomie-Zentrum, Abteilung für klinische Neurobiologie, Universitätsklinik für Neurologie, Medizinische Universität Innsbruck


  1. Fanciulli A, Wenning GK, Multiple-system atrophy. N Engl J Med 2015; 372(14):1375–6
  2. Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ et al., Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008; 71(9):670–6
  3. Köllensperger M, Geser F, Seppi K, Stampfer-Kountchev M, Sawires M, Scherfler C, et al., Red flags for multiple system atrophy. Mov Disord 2008; 23(8):1093–9
  4. Reyes JF, Rey NL, Bousset L, Melki R, Brundin P, Angot E, Alpha-synuclein transfers from neurons to oligodendrocytes. Glia 2014; 62(3):387–98
  5. Stefanova N, Kaufmann WA, Humpel C, Poewe W, Wenning GK, Systemic proteasome inhibition triggers neurodegeneration in a transgenic mouse model expressing human α-synuclein under oligodendrocyte promoter: implications for multiple system atrophy. Acta Neuropathol 2012; 124(1):51–65
  6. Stefanova N, Wenning GK, Review: Multiple system atrophy: emerging targets for interventional therapies. Neuropathol Appl Neurobiol 2016; 42(1):20–32
  7. Heras-Garvin A, Stefanova N, MSA: From basic mechanisms to experimental therapeutics. Parkinsonism Relat Disord 2020; 73:94–104
  8. Jellinger KA, Neuropathology of multiple system atrophy: new thoughts about pathogenesis. Mov Disord 2014; 29(14):1720–41
  9. Laurens B, Vergnet S, Lopez MC, Foubert-Samier A, Tison F, Fernagut PO et al., Multiple System Atrophy – State of the Art. Curr Neurol Neurosci Rep 2017; 17(5):41
  10. Levin JM, Schuberth M, Respondek M, Paul G, Mansmann F, Oertel U, Lorenzl WH, Krismer S, Seppi F, Poewe K, Wenning W, Giese G, Bötzel A, Höglinger GU, PROMESA study group. The PROMESA-protocol: progression rate of multiple system atrophy under EGCG supplementation as anti-aggregation-approach. J Neural Transm (Vienna). 2016; 123(4):439–45
  11. Levin J, Maass S, Schuberth M, Giese A, Wolfgang O, Werner P et al., PROMESA: A randomised, double-blind, placebo-controlled trial to evaluate the progression rate of MSA under EGCG supplementation as anti-aggregation-approach2018 [Link]
  12. Low PA, Robertson D, Gilman S, Kaufmann H, Singer W, Biaggioni I et al., Efficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2014; 13(3):268–75
  13. Ubhi K, Rockenstein E, Mante M, Patrick C, Adame A, Thukral M et al., Rifampicin reduces alpha-synuclein in a transgenic mouse model of multiple system atrophy. Neuroreport 2008; 19(13):1271–6
  14. Meissner W, Pavy-Le Traon A, Foubert-Samier A, Galitzky M, Laurens B, Sabatini U, Schmidhuber S, Winter D, Galabova G, Staffler G, Schneeberger A, Kutzelnigg A, Rascol O, Specific active immunotherapy (SAIT) against alpha-synuclein with AFFITOPE® PD01A and PD03A: Results from the AFF009 phase I trial [abstract]
  15. Mandler M, Valera E, Rockenstein E, Mante M, Weninger H, Patrick C et al., Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy. Mol Neurodegener 2015; 10:10
  16. Study to evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB101 Administered to Adults with Multiple System Atrophy (HORIZON) [Link]
  17. Heras-Garvin A, Weckbecker D, Ryazanov S, Leonov A, Griesinger C, Giese A et al., Anle138b modulates α-synuclein oligomerization and prevents motor decline and neurodegeneration in a mouse model of multiple system atrophy. Mov Disord 2019; 34(2):255–63
  18. Seppi K, Peralta C, Diem-Zangerl A, Puschban Z, Mueller J, Poewe W et al., Placebo-controlled trial of riluzole in multiple system atrophy. Eur J Neurol 2006; 13(10):1146–8
  19. Holmberg B, Johansson JO, Poewe W, Wenning G, Quinn NP, Mathias C et al., Safety and tolerability of growth hormone therapy in multiple system atrophy: a double-blind, placebo-controlled study. Mov Disord 2007; 22(8):1138–44
  20. Poewe W, Seppi K, Fitzer-Attas CJ, Wenning GK, Gilman S, Low PA et al., Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy: a randomised, placebo-controlled trial. Lancet Neurol 2015; 14(2):145–52
  21. Saccà F, Marsili A, Quarantelli M, Brescia Morra V, Brunetti A, Carbone R et al., A randomized clinical trial of lithium in multiple system atrophy. J Neurol 2013; 260(2):458–61
  22. Novak P, Pimentel Maldonado DA, Novak V, Safety and preliminary efficacy of intranasal insulin for cognitive impairment in Parkinson disease and multiple system atrophy: A double-blinded placebo-controlled pilot study. PLoS One 2019; 14(4):e0214364
  23. Lee PH, Kim JW, Bang OY, Ahn YH, Joo IS, Huh K, Autologous mesenchymal stem cell therapy delays the progression of neurological deficits in patients with multiple system atrophy. Clin Pharmacol Ther 2008; 83(5):723–30
  24. Lee PH, Lee JE, Kim HS, Song SK, Lee HS, Nam HS et al., A randomized trial of mesenchymal stem cells in multiple system atrophy. Ann Neurol 2012; 72(1):32–40
  25. Singer W, Dietz AB, Zeller AD, Gehrking TL, Schmelzer JD, Schmeichel AM et al., Intrathecal administration of autologous mesenchymal stem cells in multiple system atrophy. Neurology 2019; 93(1):e77–e87
  26. Low PA, Gilman S, Are trials of intravascular infusions of autologous mesenchymal stem cells in patients with multiple system atrophy currently justified, and are they effective? Ann Neurol 2012; 72(1):4–5
  27. Tllsh2910 for Ataxia and Gut Microbiota Alteration in Patients of Multiple System Atrophy [Link]
  28. Study of BHV-3241 in Subjects With Multiple System Atrophy (M-STAR) [Link]
  29. A Futility Trial of Sirolimus in Multiple System Atrophy [Link]
  30. A Randomized, Double-Blind, Placebo-Controlled, Multicenter study to Evaluate Efficacy and Safety of MSA-01 in Patients with Multiple system atrophy [Link]
  31. Stamler D, Bradbury M, Wong CW, Offman E, A Phase 1 Study of PBT434, a Novel Small Molecule Inhibitor of α-Synuclein Aggregation, in Adult and Older Adult Volunteers (4871). Neurol 2020 (April 14); 94(15 Supplement) [Link]
  32. 32 Novak P, Williams A, Ravin P, Zurkiya O, Abduljalil A, Novak V, Treatment of multiple system atrophy using intravenous immunoglobulin. BMC Neurol 2012; 12:131
  33. 33 Castro Caldas A, Levin J, Djaldetti R, Rascol O, Wenning G, Ferreira JJ et al., Critical appraisal of clinical trials in multiple system atrophy: Toward better quality. Mov Disord 2017; 32(10):1356–64

neuro 03|2020

Herausgeber: Österreichische Gesellschaft für Neurologie, Univ.-Prof. Dr. Thomas Berger, MSc, Präsident der ÖGN
Publikationsdatum: 2020-10-01